Michael Andreeff

65PUBLICATIONS
271CO-AUTHORS
Molecular targetsGene and molecular therapyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Aug 17, 2026
Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies.

|Jul 13, 2026
The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML.

|Jul 06, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

|Jun 22, 2026
Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

|Jun 11, 2026
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

|Jun 01, 2026
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

Pageof 11

Frequent Collaborators

23 joint publications

Naval G Daver

18 joint publications

Courtney DiNardo

18 joint publications

Marina Y Konopleva

17 joint publications

Hagop M Kantarjian